411 related articles for article (PubMed ID: 29424035)
1. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
3. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
4. Descending serotonergic and noradrenergic systems do not regulate the antipruritic effects of cannabinoids.
Todurga ZG; Gunduz O; Karadag CH; Ulugol A
Acta Neuropsychiatr; 2016 Dec; 28(6):321-326. PubMed ID: 27805543
[TBL] [Abstract][Full Text] [Related]
5. Blockade of cannabinoid CB1 and CB2 receptors does not prevent the antipruritic effect of systemic paracetamol.
Saglam G; Gunduz O; Ulugol A
Acta Neurol Belg; 2014 Dec; 114(4):307-9. PubMed ID: 24399199
[TBL] [Abstract][Full Text] [Related]
6. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Johanek LM; Simone DA
Pain; 2004 Jun; 109(3):432-442. PubMed ID: 15157704
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia–reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS.
González C; Herradón E; Abalo R; Vera G; Pérez-Nievas BG; Leza JC; Martín MI; López-Miranda V
Diabetes Metab Res Rev; 2011 May; 27(4):331-40. PubMed ID: 21309057
[TBL] [Abstract][Full Text] [Related]
8. The cannabinoid receptor agonist WIN 55,212-2 inhibits antigen-induced plasma extravasation in guinea pig airways.
Fukuda H; Abe T; Yoshihara S
Int Arch Allergy Immunol; 2010; 152(3):295-300. PubMed ID: 20150748
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
10. Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice.
Ikeda H; Ikegami M; Kai M; Ohsawa M; Kamei J
Neuroscience; 2013 Oct; 250():446-54. PubMed ID: 23892011
[TBL] [Abstract][Full Text] [Related]
11. Contribution of spinal 5-HT
Aksu AG; Gunduz O; Ulugol A
Can J Physiol Pharmacol; 2018 Jun; 96(6):618-623. PubMed ID: 29406831
[TBL] [Abstract][Full Text] [Related]
12. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
14. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat.
Abalo R; Cabezos PA; Vera G; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2010 Jun; 22(6):694-e206. PubMed ID: 20132133
[TBL] [Abstract][Full Text] [Related]
15. Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone.
Elmas P; Ulugol A
J Neural Transm (Vienna); 2013 Nov; 120(11):1533-8. PubMed ID: 23784345
[TBL] [Abstract][Full Text] [Related]
16. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain.
Benamar K; Geller EB; Adler MW
J Pharmacol Exp Ther; 2008 May; 325(2):641-5. PubMed ID: 18281594
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats.
Fernández-López D; Martínez-Orgado J; Nuñez E; Romero J; Lorenzo P; Moro MA; Lizasoain I
Pediatr Res; 2006 Aug; 60(2):169-73. PubMed ID: 16864698
[TBL] [Abstract][Full Text] [Related]
18. CB
Zheng T; Zhang R; Zhang T; Zhang MN; Xu B; Song JJ; Li N; Tang HH; Wang P; Wang R; Fang Q
Brain Res; 2018 Feb; 1680():155-164. PubMed ID: 29274880
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model.
Cui JH; Kim WM; Lee HG; Kim YO; Kim CM; Yoon MH
Neurosci Lett; 2011 Apr; 493(3):67-71. PubMed ID: 21195743
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress.
Ganon-Elazar E; Akirav I
Neuropsychopharmacology; 2012 Jan; 37(2):456-66. PubMed ID: 21918506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
